2002 DEA History Safety 
Cannabis Law Report
JULY 9, 2021
Drug Enforcement Agency (“DEA”). Some physicians and therapists have argued that the Right to Try Act permits them to administer psilocybin to terminally ill patients (since studies are well past the Phase 1 stage), but the DEA has met this with resistance given psilocybin’s status as a Schedule I drug. AIMS Institute, PLLC.
Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,
Expert insights. Personalized for you.
105 
Let's personalize your content